


Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.
PROMACTA (eltrombopag) is an oral medication that works by activating the thrombopoietin receptor, leading to increased platelet production. It is available in tablet and oral suspension forms.
The drug is metabolized extensively and has specific pharmacokinetic properties that require careful dosing adjustments in certain populations, such as those with hepatic impairment or East-Southeast-Asian ancestry. It is designed to help manage low platelet counts in various medical conditions, with a focus on reducing bleeding risks.
Treatment of thrombocytopenia in adults and pediatric patients (≥1 year) with persistent or chronic ITP who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.
Treatment of thrombocytopenia in patients with chronic hepatitis C to enable initiation and maintenance of interferon-based therapy.
First-line treatment of severe aplastic anemia in combination with immunosuppressive therapy (IST) in adults and pediatric patients (≥2 years).
Treatment of severe aplastic anemia in patients with an insufficient response to immunosuppressive therapy.
Administer orally once daily on an empty stomach or with a low-calcium meal (≤50 mg calcium). Avoid concurrent use with polyvalent cation-containing products (e.g., antacids, dairy) within 2 hours before or 4 hours after dosing.
Dosing is individualized based on indication, age, hepatic function, and ethnicity (e.g., reduced initial doses for East/Southeast Asian patients or those with hepatic impairment).
Monitor platelet counts regularly and adjust dose to achieve target platelet levels (e.g., ≥50×10⁹/L for ITP). Maximum daily doses: 75 mg (ITP), 100 mg (hepatitis C), 150 mg (SAA).
Oral suspension must be reconstituted with water and administered immediately (within 30 minutes).
